APOFERRITIN AS A TARGETED DRUG DELIVERY SYSTEM

conference paper

English

Conventional cancer treatment often effects normal cells and has many side effects. These can be addressed by the use of nanomedicine, especially its platform nanotransporters, in which cytostatic drug can be encapsulated. These nanotransporters can be dispersed in tumors through relatively large pores in tumor blood vessels but not in normal blood vessels. The nanotransporters can be coupled with antibodies, thus allowing targeted delivery of drugs. For this coupling we chose the method using linker, small peptide that interacts with Fc region of IgG antibodies, presenting the antigen binding site facing out. The aim of this experiment was to create, characterize and test a nanotransporter based on apoferritin nanocage with encapsulated doxorubicin, modified with specific antibody. As a linker, heptapeptide HWRGWVC was used. Cysteine has known affinity towards gold, two methods of apoferritin surface modification were proposed and better results were obtained with apoferritin modified with gold nanoparticles. The presence of gold on apoferritin was proved by separation in polyacrylamide gel electrophoresis (PAGE), followed by inductively coupled plasma mass spectrometric (ICP-MS) measurement. Enzyme-linked immunosorbent assay (ELISA) was used to prove the apoferritin ability to specifically bind to target cells. Apoferritin retained its ability to open and release doxorubicin in low pH. This is very convenient, since there is lower pH in tumors due to hypoxemia.

apoferritin; doxorubicin; theranostics; antibodies; targeted delivery

DOSTÁLOVÁ, S.; KONEČNÁ, R.; BLAŽKOVÁ, I.; VACULOVIČOVÁ, M.; KOPEL, P.; KŘÍŽKOVÁ, S.; VACULOVIČ, T.; ADAM, V.; KIZEK, R.

21. 11. 2013

978-80-7375-908-7

MendelNet 2013

908

912

5